
New Ovarian Cancer Drug Combo Shows 42% Response Rate vs 16% with Standard Therapy
Low-grade serous ovarian cancer (LGSC) has long been one of the most challenging forms of ovarian cancer to treat. It affects younger women, resists standard chemotherapy, and often leads to late recurrences.